Skip to content
Friday 7 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Tuesday 01 July 2025 4:40 pm

Astrazeneca chief ‘wants to shift London listing to US’

By: Samuel Norman

Senior City Reporter

Add as a preferred source on Google
Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
Astrazeneca shareholders have questioned the possible merger

The boss of Britain’s most valuable company, Astrazeneca, has reportedly voiced his preference to move the firm’s stock market listing to the United States.

Sir Pascal Soriot, who has been at the helm of the pharma juggernaut since 2012, is said to have spoken privately about his desire to abandon the UK listing in favour of the US.

It’s thought board members, along with the UK government, would be expected to push back against such a move due to the firm’s standing in the market.

Soriot’s wishes, as revealed by The Times, would mark a crushing blow to the London Stock Exchange due to the firm’s £160bn market cap – the highest on the market.

The FTSE 100 chief has been vocal about Europe falling behind peers US and China on new medicine innovation.

Soriot denied a rift with the Labour government earlier this year after abandoning plans for a £450m vaccine factory amid questions over the “timing and reduction of the final offer” of support from the government.

Astrazeneca declined to comment to Morning Wire.

Read more

Astrazeneca share price tumbles on $400bn megamerger talks

Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure

Astrazeneca threatens a fatal blow

The loss of Astrazeneca would raise drastic questions about the stability and health of the London market.

In 2024, the LSE suffered its biggest exodus in 15 years as 88 firms ditched or transferred their primary listing. This included Paddy Power owner Flutter and tech darling Darktrace.

The woes have continued into 2025 with a combination of takeovers and delistings leading to a struggling market.

UK fintech Wise dealt a blow to the London market after transferring its primary listing to the US. Meanwhile, last month three billion-pound swoops resulted in foreign giants snapping up London-listed assets.

In a bid to boost investment in UK assets and crowd in further liquidity to maintain listings, London Stock Exchange chief Julia Hoggett has suggested a new “Tell Sid” advertising campaign.

But this has faced criticism from LSEG’s former boss Xavier Rolet, who blasted stewards of UK capital markets for focusing on “gimmicks and quick headline-grabbing fixes” to liquidity levels.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Markets
  • Business
  • Pharma

People & Organisations

  • Astrazenaca
  • Astrazeneca
  • FTSE
  • ftse 100
  • Government
  • listing
  • London
  • London Stock Exchange
  • london stock exchange group
  • London Stock Exhange
  • LSE
  • lse exodus
  • LSEG
  • Pascal Soriot
  • Pharma

Trending Articles

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Rupert Lowe axes pensions triple lock and pledges tax cuts in economic plan

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • As it happened: Stocks rise as oil fluctuates after Red Sea attack; US-Iran deal ‘being circulated’

More from Morning Wire

  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Glencore targets secondary listing in Australia as London loses mining shine

    Mining
    Glencore corporate headquarters building exterior with the company logo sign, representing the commodities firm.
  • London’s IPO lull expected to last into 2027

    Markets
    The London Stock Exchange has had a challenging 2024 so far, although bankers are eying a rebound for IPOs
  • As it happened: UK stocks cool after Astrazeneca drags; Trump and Iran clash over peace talks

    FTSE 100 Live
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • Wise denied US banking licence in blow to expansion plans

    Banking
    Wise outlined plans to shift its primary listing to the US in June.
  • If Burnham wants growth he’ll have to save the City

    Business
    London Stock Exchange building exterior on a busy trading day with bustling city atmosphere and iconic architecture
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook